Lilly Xigris Efficacy Driven By Chronically Ill Patients, FDA Analyses Show
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Xigris’ greater efficacy in patients with chronic health problems may account for the minimal effect on hospital discharge seen in the pivotal trial of the sepsis agent, FDA review documents maintain.